Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04743674 · ClinicalTrials.gov registry record

Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment

A clinical trial of Cervical Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Recruiting
Registry status
30
Enrollment target
2
Study locations

NCT04743674: Recruiting study of Cervical Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT04743674 is a study of Cervical Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04743674, a study of Cervical Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.

RECRUITING
Registry status
30 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.

Primary Outcome

We will quantify ctHPVDNA levels in blood plasma and TrHPVDNA in urine from patients with cervical cancer at time of diagnosis.

Conditions Studied

Cervical Cancer

Study Locations (2)

North Carolina

  • Melissa Knutsen - Chapel Hill

Other

  • Kamuzu Central Hospital - Lilongwe

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-05-03
Est. Completion 2027-01-15
UNC Lineberger Comprehensive Cancer Center

366 total trials

What NCT04743674 shows while recruiting

NCT04743674 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT04743674 reports a single indexed study location in North Carolina, Other.

Frequently Asked Questions

What is clinical trial NCT04743674 about?

NCT04743674 is a clinical study titled "Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment". The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of ce...

What is the current status of trial NCT04743674?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-05-03. Estimated completion is 2027-01-15.

What conditions does trial NCT04743674 study?

This clinical trial studies the following conditions: Cervical Cancer.

Who is sponsoring clinical trial NCT04743674?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04743674 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04743674's enrollment target sits among peer trials

30 119th of 144 higher than 22 of 144 other Cervical Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04743674

Source: ClinicalTrials.gov NCT04743674, the US trial registry maintained by the National Library of Medicine. NCT04743674 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.